Amarantus Announces Positive Analytical Performanc
Post# of 30028
Posted On: 07/14/2014 9:01:12 AM
Amarantus Announces Positive Analytical Performance Data Poster Presentation for LymPro Test (R) at AAIC 2014
Download PDF
SAN FRANCISCO and GENEVA, July 14, 2014 (GLOBE NEWSWIRE) -- Amarantus Bioscience Holdings, Inc. (OTCQB:AMBS), a biotechnology company focused on the discovery and development of novel diagnostics and therapeutics related to endoplasmic reticulum stress, cell cycle dysregulation, neurodegeneration and apoptosis, today announced positive analytical performance data for the Company's proprietary cell cycle dysregulation diagnostic blood assay LymPro Test®, currently under development for Alzheimer's disease diagnosis. The analytical data package, produced at the Company's contract laboratory BD Biosciences, provides the basis for reproducible clinical performance assessment of LymPro Test®. The Company has performance univariate and multivariate analytical data analyses in an Alzheimer's population vs. a non-Alzheimer's population (cognitively intact, Parkinson's dementia and vascular dementia) to assess clinical performance. The Company will present pilot clinical performance data, and an up-to 6 year longitudinal assessment of the patients' clinical diagnosis change over time, in two complementary poster presentations on Tuesday July 15th, 2014 at 11:45am local at AAIC 2014 in Copenhagen, Denmark (Poster position 117 and 118).
"We are pleased with the reproducibility we have seen with the assay at BD," commented Paul Jorgensen, Head of Diagnostics Product Development at Amarantus. "We evaluated various conditions for assay performance and were able to clearly demonstrate suitable analytical performance that will underpin the validity of the ability of LymPro to differentiate Alzheimer's from non-Alzheimer's using both univariate and multivariate models. We are pleased to be sharing the data, along with a scientific and clinical data summary to support the cell cycle dysregulation hypothesis in Alzheimer's disease."
The contract laboratory evaluated the ability of specific mitogens to upregulate the cell surface marker CD69 in various subpopulations of peripheral blood lymphocytes. The data showed clear and consistent measurements of CD69 on an individual lymphocyte subpopulation basis, and an overall lymphocyte population basis. This confirms previously published work on LymPro (Stieler et al, 2001, and Stieler et al, 2012) and allows Amarantus to generate meaningful univariate measurements and multivariate models that may allow for the differentiation of Alzheimer's patients from non-Alzheimer's patients. A copy of the poster presentation can be found at http://www.amarantus.com/aJCPUuWU.
Download PDF
SAN FRANCISCO and GENEVA, July 14, 2014 (GLOBE NEWSWIRE) -- Amarantus Bioscience Holdings, Inc. (OTCQB:AMBS), a biotechnology company focused on the discovery and development of novel diagnostics and therapeutics related to endoplasmic reticulum stress, cell cycle dysregulation, neurodegeneration and apoptosis, today announced positive analytical performance data for the Company's proprietary cell cycle dysregulation diagnostic blood assay LymPro Test®, currently under development for Alzheimer's disease diagnosis. The analytical data package, produced at the Company's contract laboratory BD Biosciences, provides the basis for reproducible clinical performance assessment of LymPro Test®. The Company has performance univariate and multivariate analytical data analyses in an Alzheimer's population vs. a non-Alzheimer's population (cognitively intact, Parkinson's dementia and vascular dementia) to assess clinical performance. The Company will present pilot clinical performance data, and an up-to 6 year longitudinal assessment of the patients' clinical diagnosis change over time, in two complementary poster presentations on Tuesday July 15th, 2014 at 11:45am local at AAIC 2014 in Copenhagen, Denmark (Poster position 117 and 118).
"We are pleased with the reproducibility we have seen with the assay at BD," commented Paul Jorgensen, Head of Diagnostics Product Development at Amarantus. "We evaluated various conditions for assay performance and were able to clearly demonstrate suitable analytical performance that will underpin the validity of the ability of LymPro to differentiate Alzheimer's from non-Alzheimer's using both univariate and multivariate models. We are pleased to be sharing the data, along with a scientific and clinical data summary to support the cell cycle dysregulation hypothesis in Alzheimer's disease."
The contract laboratory evaluated the ability of specific mitogens to upregulate the cell surface marker CD69 in various subpopulations of peripheral blood lymphocytes. The data showed clear and consistent measurements of CD69 on an individual lymphocyte subpopulation basis, and an overall lymphocyte population basis. This confirms previously published work on LymPro (Stieler et al, 2001, and Stieler et al, 2012) and allows Amarantus to generate meaningful univariate measurements and multivariate models that may allow for the differentiation of Alzheimer's patients from non-Alzheimer's patients. A copy of the poster presentation can be found at http://www.amarantus.com/aJCPUuWU.
(0)
(0)Amarantus Bioscience Holdings (AMBS) Stock Research Links
Scroll down for more posts ▼